AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Clinical Trials
3.8k
Trial Phases
6 Phases
Drug Approvals
31
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (2772 trials with phase data)• Click on a phase to view related trials
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Biological: AZD0120 - Regimen 1Biological: AZD0120 - Regimen 2
- First Posted Date
- 2025-11-04
- Last Posted Date
- 2025-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT07224373
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Drug: Baxdrostat/dapagliflozinDrug: Baxdrostat/Placebo
- First Posted Date
- 2025-10-30
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 218
- Registration Number
- NCT07222917
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-29
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT07222254
Study of Patient With Frequent COPD Exacerbations
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2025-10-29
- Last Posted Date
- 2025-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT07221981
- Locations
- 🇷🇺
Research site, Yekaterinburg, Russia
🇷🇺Research site "OOO Energy of health", Saint Petersburg, Russia
Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
- Conditions
- Neurofibromatosis Type 1
- First Posted Date
- 2025-10-27
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT07221331
- Prev
- 1
- 2
- 3
- 4
- 5
- 670
- Next
News
Neok Bio Emerges with $75M to Develop Dual-Targeting ADCs for Cancer Treatment
Neok Bio launched with $75 million in Series A funding to develop bispecific antibody-drug conjugates that simultaneously target two distinct cancer proteins.
BioInvent Reports Promising Safety and Efficacy Data for Triple Combination Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma
BioInvent will present early Phase 2a data at ASH 2025 showing that the triple combination of BI-1206, rituximab, and acalabrutinib is safe and well-tolerated in relapsed/refractory NHL patients.
FDA Proposes Streamlined Biosimilar Approval Process to Reduce Drug Costs by 50%
The FDA announced new draft guidance to simplify biosimilar approval by reducing clinical testing requirements and shortening development timelines.
Alembic Pharmaceuticals Receives FDA Approval for Generic Ticagrelor 60mg Tablets for Acute Coronary Syndrome
Alembic Pharmaceuticals Limited received final FDA approval for its generic ticagrelor tablets 60mg, therapeutically equivalent to AstraZeneca's Brilinta.
AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
Trump Administration Secures Deal with EMD Serono to Cut Fertility Drug Prices by Up to 84%
President Trump announced a deal with EMD Serono to reduce fertility medication costs, with Gonal-f available at an 84% discount for IVF patients.
Cellectis Reports Promising Phase 1 Results for Lasme-cel in Relapsed/Refractory B-ALL, Advances to Pivotal Phase 2
Cellectis' allogeneic CAR-T therapy lasme-cel demonstrated a 100% overall response rate in the target Phase 2 population of heavily pretreated relapsed/refractory B-cell acute lymphoblastic leukemia patients.
Takeda Expands AI Drug Discovery Partnership with Nabla Bio in $1B+ Deal
Takeda Pharmaceutical has signed a second multi-year AI partnership with Nabla Bio, potentially worth over $1 billion including milestone payments, to accelerate early-stage drug discovery using artificial intelligence.
Activist Investor Shah Capital Calls for Novavax Sale Amid COVID Vaccine Market Share Struggles
Shah Capital, Novavax's second-largest shareholder with a 7.2% stake, has urged the company's board to pursue a sale, citing three consecutive years of poor COVID-19 vaccine performance.
Ona Therapeutics Appoints ADC Development Veteran Dr. Antoine Yver as Board Chair to Advance Breast Cancer Pipeline
Ona Therapeutics has appointed Dr. Antoine Yver, a veteran with over 35 years of oncology drug development experience, as Chair of its Board of Directors to guide the company's transition to clinical-stage operations.